JP6562897B2 - 細胞培養上清および生体液からの微小胞の単離および精製のための方法 - Google Patents

細胞培養上清および生体液からの微小胞の単離および精製のための方法 Download PDF

Info

Publication number
JP6562897B2
JP6562897B2 JP2016501590A JP2016501590A JP6562897B2 JP 6562897 B2 JP6562897 B2 JP 6562897B2 JP 2016501590 A JP2016501590 A JP 2016501590A JP 2016501590 A JP2016501590 A JP 2016501590A JP 6562897 B2 JP6562897 B2 JP 6562897B2
Authority
JP
Japan
Prior art keywords
microvesicles
isolated
cells
bone marrow
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518109A5 (https=
JP2016518109A (ja
Inventor
エバンジェロス・ブイ・バディアバス
アーサラン・キュー・シャビール
スティーブン・シー・デイビス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of JP2016518109A publication Critical patent/JP2016518109A/ja
Publication of JP2016518109A5 publication Critical patent/JP2016518109A5/ja
Priority to JP2019105087A priority Critical patent/JP7405389B2/ja
Application granted granted Critical
Publication of JP6562897B2 publication Critical patent/JP6562897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
JP2016501590A 2013-03-13 2014-03-12 細胞培養上清および生体液からの微小胞の単離および精製のための方法 Active JP6562897B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019105087A JP7405389B2 (ja) 2013-03-13 2019-06-05 細胞培養上清および生体液からの微小胞の単離および精製のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778591P 2013-03-13 2013-03-13
US61/778,591 2013-03-13
PCT/US2014/024629 WO2014159662A1 (en) 2013-03-13 2014-03-12 Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019105087A Division JP7405389B2 (ja) 2013-03-13 2019-06-05 細胞培養上清および生体液からの微小胞の単離および精製のための方法

Publications (3)

Publication Number Publication Date
JP2016518109A JP2016518109A (ja) 2016-06-23
JP2016518109A5 JP2016518109A5 (https=) 2017-04-13
JP6562897B2 true JP6562897B2 (ja) 2019-08-21

Family

ID=51625222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016501590A Active JP6562897B2 (ja) 2013-03-13 2014-03-12 細胞培養上清および生体液からの微小胞の単離および精製のための方法
JP2019105087A Active JP7405389B2 (ja) 2013-03-13 2019-06-05 細胞培養上清および生体液からの微小胞の単離および精製のための方法
JP2022027857A Active JP7417301B2 (ja) 2013-03-13 2022-02-25 細胞培養上清および生体液からの微小胞の単離および精製のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019105087A Active JP7405389B2 (ja) 2013-03-13 2019-06-05 細胞培養上清および生体液からの微小胞の単離および精製のための方法
JP2022027857A Active JP7417301B2 (ja) 2013-03-13 2022-02-25 細胞培養上清および生体液からの微小胞の単離および精製のための方法

Country Status (13)

Country Link
US (4) US10500231B2 (https=)
EP (3) EP4218774A1 (https=)
JP (3) JP6562897B2 (https=)
CN (2) CN105209881B (https=)
AU (4) AU2014244618A1 (https=)
CA (1) CA2906502A1 (https=)
DK (2) DK3677271T3 (https=)
ES (2) ES2778098T3 (https=)
FI (1) FI3677271T3 (https=)
HU (2) HUE049003T2 (https=)
PL (2) PL2972193T3 (https=)
PT (2) PT2972193T (https=)
WO (1) WO2014159662A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105209881B (zh) * 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
US9687511B2 (en) 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
US11160904B2 (en) 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
EP3267965A4 (en) * 2015-03-11 2018-11-14 Atta Behfar Exosome delivery technology
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
WO2017023690A1 (en) * 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair
KR102418785B1 (ko) * 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR102475127B1 (ko) * 2015-09-30 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 포함하는 탈모 방지 또는 육모 촉진용 조성물
JP2019501179A (ja) * 2015-12-30 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞由来ベシクルの向上された生成および単離のための方法
MX2018008707A (es) * 2016-01-19 2019-03-06 Siren Matti J Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer.
KR102475129B1 (ko) * 2016-03-22 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2018039100A2 (en) * 2016-08-23 2018-03-01 Albert Einstein College Of Medicine, Inc. Stem cell-produced microvesicles for treating tendon pathologies
EP3568143B1 (en) * 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
EP3660142A4 (en) 2017-07-26 2021-05-05 Rosetta Exosome METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS
WO2019023584A1 (en) * 2017-07-27 2019-01-31 Cornell University FIXING AND RETENTION OF EXTRACELLULAR VESICLES
CA3076610A1 (en) * 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
US11471559B2 (en) * 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
CA3089825C (en) 2018-01-29 2022-08-30 Forever Labs, Inc. System and method for isolating extracellular vesicles
CN108414334A (zh) * 2018-02-23 2018-08-17 中山大学附属第医院 一种从精液中分离提纯外泌体的方法
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
AU2020228303B2 (en) * 2019-02-28 2025-09-18 Merakris Therapeutics Llc Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111893093A (zh) * 2020-08-03 2020-11-06 沈阳三禾生物科技有限公司 一种脐带间充质干细胞来源的超微因子的制备方法
KR20230074475A (ko) 2020-08-21 2023-05-30 더 유니버시티 오브 마이애미 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법
WO2022080461A1 (ja) * 2020-10-16 2022-04-21 富士フイルム和光純薬株式会社 細胞外小胞の産生用培地、培地キット、添加剤及び細胞外小胞の産生方法
CN114081900B (zh) * 2021-02-24 2024-11-22 济宁医学院附属医院 间充质干细胞来源的纳米微囊泡在制备治疗子痫前期的药物中的应用
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
EP4511045A1 (en) 2022-04-19 2025-02-26 University of Miami Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease
KR20240028586A (ko) * 2022-08-24 2024-03-05 (주) 테라베스트 인간 세포 유래 미세소포체 및 히알루론산 또는 콜라겐을 포함하는 조성물 및 이의 용도
CN116898781B (zh) * 2023-02-07 2025-08-15 中国中医科学院中医基础理论研究所 大麦苗外泌体在制备具有抗衰老修护作用的产品中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
ATE521353T1 (de) 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
AU2001297880B2 (en) * 2000-11-30 2007-05-31 Stemron Inc. Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
CA3061952C (en) 2006-03-09 2022-07-19 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
EP1939218A1 (en) 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
WO2008112125A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
EP2719773A3 (en) 2007-06-15 2014-07-30 The Ohio State University Research Foundation miRNA as marker for acute lamphomic leucemia
WO2009015357A1 (en) 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
EP2209481B1 (en) * 2007-10-15 2013-03-13 Fresenius Medical Care Deutschland GmbH Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
ES2523098T3 (es) * 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
CA2711218C (en) 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
US20120058492A1 (en) 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
EP2245199B1 (en) * 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
AU2009236653B2 (en) * 2008-04-16 2014-09-25 Biogen Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
US8512695B2 (en) 2008-10-21 2013-08-20 The General Hospital Corporation Method of preventing fat graft resorption by administering fat-derived cells and poloxamer P 188
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
EP3569254B1 (en) 2009-04-17 2022-07-20 Oxford University Innovation Limited Composition for delivery of genetic material
BRPI0900815A2 (pt) 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
MX2011013452A (es) 2009-07-02 2012-04-30 Ith Immune Therapy Holdings Ab Tratamiento de cancer basado en exosomas.
BR112012001077A2 (pt) * 2009-07-16 2020-08-11 The General Hospital Corporation extração de ácido nucleico, métodos para avaliar a qualidade de uma extração de ácido nucleico e de uma amostra biológica, para ober ácido nucleico a partir de uma amostra biológica, para analisar rna de microvesículas e para diagnosticar e monitorar um indivíduo, e, kit
CN102812362B (zh) 2010-01-08 2015-02-11 卡瓦迪斯有限责任公司 用于预测心血管事件的外来体生物标志物的确定
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
CN103079592B (zh) * 2010-07-01 2015-10-21 浦项工科大学校产学协力团 使用来自细胞的微泡治疗和诊断癌症的方法
CA2845280A1 (en) * 2010-08-13 2012-02-16 Paul Shiels Therapeutic uses of microvesicles and related micrornas
US20120053976A1 (en) 2010-08-31 2012-03-01 Xerox Corporation System and method for determining whether service costs can be reduced
JP5911874B2 (ja) * 2010-10-18 2016-04-27 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 発毛を促進又は増強するためのエキソソームの使用
US20120093885A1 (en) * 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2012110253A2 (en) 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
WO2012110099A1 (en) 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
WO2012126531A1 (en) 2011-03-24 2012-09-27 Cavadis B.V. Method for diagnosing acute coronary syndrome (acs)
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
SG195306A1 (en) 2011-06-08 2013-12-30 Agency Science Tech & Res Purification of biological products by constrained cohydration chromatography
EP2734543B1 (en) 2011-07-24 2018-10-03 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
CN103842522A (zh) 2011-08-05 2014-06-04 路易斯维尔大学研究基金会 微rna生物标记物
EP2604288A1 (en) 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoparticles and uses thereof
US20150052361A1 (en) 2011-12-23 2015-02-19 Appbyyou Gmbh Method for setting up an encrypted connection between two communication appliances following prior key interchange via a shorthaul connection
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
WO2013188832A1 (en) 2012-06-14 2013-12-19 System Biosciences, Llc Methods for microvesicle isolation and selective removal
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
ES2686129T3 (es) 2012-11-13 2018-10-16 Codiak Biosciences, Inc. Administración de agentes terapéuticos
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105209881B (zh) 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
SG11201601939VA (en) 2013-09-16 2016-04-28 Agency Science Tech & Res Method
US20170173113A1 (en) 2014-03-13 2017-06-22 Research Institute At Nationwide Children's Hospital Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
EP3193890A4 (en) 2014-09-15 2018-03-14 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
KR20170085010A (ko) 2016-01-12 2017-07-21 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CA3076610A1 (en) 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
KR20230074475A (ko) 2020-08-21 2023-05-30 더 유니버시티 오브 마이애미 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법

Also Published As

Publication number Publication date
HUE049003T2 (hu) 2020-09-28
EP2972193A4 (en) 2016-09-07
PL3677271T3 (pl) 2023-08-21
AU2022206811B2 (en) 2024-08-15
JP2022084634A (ja) 2022-06-07
EP4218774A1 (en) 2023-08-02
US20160184363A1 (en) 2016-06-30
US20260091064A1 (en) 2026-04-02
AU2018211351C1 (en) 2020-12-10
WO2014159662A1 (en) 2014-10-02
CN105209881B (zh) 2021-01-22
FI3677271T3 (fi) 2023-06-06
US10500231B2 (en) 2019-12-10
PT2972193T (pt) 2020-04-23
EP3677271A1 (en) 2020-07-08
US11730768B2 (en) 2023-08-22
DK2972193T3 (da) 2020-03-23
AU2020223723A1 (en) 2020-09-10
JP7405389B2 (ja) 2023-12-26
ES2949637T3 (es) 2023-10-02
JP2019195331A (ja) 2019-11-14
JP7417301B2 (ja) 2024-01-18
CN112795533A (zh) 2021-05-14
US20200163999A1 (en) 2020-05-28
EP3677271B1 (en) 2023-04-19
AU2014244618A1 (en) 2015-10-08
HUE062348T2 (hu) 2023-10-28
EP2972193B1 (en) 2019-12-18
US12453745B2 (en) 2025-10-28
DK3677271T3 (da) 2023-05-22
US20230364150A1 (en) 2023-11-16
AU2022206811A1 (en) 2022-08-18
CN105209881A (zh) 2015-12-30
AU2018211351A1 (en) 2018-08-23
PL2972193T3 (pl) 2020-08-24
PT3677271T (pt) 2023-05-31
AU2018211351B2 (en) 2020-05-28
CA2906502A1 (en) 2014-10-02
ES2778098T3 (es) 2020-08-07
JP2016518109A (ja) 2016-06-23
EP2972193A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP7417301B2 (ja) 細胞培養上清および生体液からの微小胞の単離および精製のための方法
JP7525396B2 (ja) 表皮水疱症を処置するための方法及び組成物
US20180104186A1 (en) Methods and compositions for the treatment of epidermolysis bullosa
CN115537389A (zh) 具有炎症调控功能的脐带间充质干细胞源外泌体的制法
Öztürk et al. Immune regulation is more effective in the U937 inflammation model with mesenchymal stem cell extracellular vesicles stimulated by pro-inflammatory cytokines
HK40088378A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2024101047A1 (ja) 組成物およびその用途
HK40032447A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HK40032447B (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
EA047075B1 (ru) Способы и композиции для лечения буллезного эпидермолиза

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190605

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190723

R150 Certificate of patent or registration of utility model

Ref document number: 6562897

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250